Stryker Co. (NYSE:SYK) CFO Glenn S. Boehnlein sold 750 shares of the firm’s stock in a transaction on Monday, April 16th. The stock was sold at an average price of $160.00, for a total transaction of $120,000.00. Following the completion of the sale, the chief financial officer now directly owns 3,535 shares in the company, valued at approximately $565,600. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
NYSE:SYK traded up $1.11 during mid-day trading on Tuesday, hitting $163.17. 526,750 shares of the company’s stock were exchanged, compared to its average volume of 1,283,985. Stryker Co. has a one year low of $130.06 and a one year high of $170.00. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.29 and a quick ratio of 1.59. The firm has a market capitalization of $59,324.56, a P/E ratio of 25.13, a PEG ratio of 2.28 and a beta of 0.70.
Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $1.96 EPS for the quarter, topping the consensus estimate of $1.95 by $0.01. Stryker had a net margin of 8.20% and a return on equity of 24.56%. The business had revenue of $3.47 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same quarter in the previous year, the firm posted $1.78 earnings per share. Stryker’s quarterly revenue was up 9.9% on a year-over-year basis. equities research analysts expect that Stryker Co. will post 7.12 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 30th. Investors of record on Thursday, March 29th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 1.15%. The ex-dividend date is Wednesday, March 28th. Stryker’s payout ratio is currently 28.97%.
A number of large investors have recently bought and sold shares of the stock. Advisor Partners LLC boosted its stake in Stryker by 7.2% during the fourth quarter. Advisor Partners LLC now owns 4,827 shares of the medical technology company’s stock worth $779,000 after acquiring an additional 326 shares in the last quarter. Putnam FL Investment Management Co. boosted its stake in Stryker by 0.7% during the fourth quarter. Putnam FL Investment Management Co. now owns 44,867 shares of the medical technology company’s stock worth $6,947,000 after acquiring an additional 332 shares in the last quarter. Founders Capital Management LLC boosted its stake in Stryker by 1.4% during the fourth quarter. Founders Capital Management LLC now owns 25,790 shares of the medical technology company’s stock worth $3,993,000 after acquiring an additional 350 shares in the last quarter. LS Investment Advisors LLC boosted its stake in Stryker by 3.6% during the fourth quarter. LS Investment Advisors LLC now owns 10,249 shares of the medical technology company’s stock worth $1,587,000 after acquiring an additional 354 shares in the last quarter. Finally, Penserra Capital Management LLC boosted its stake in Stryker by 18.6% during the fourth quarter. Penserra Capital Management LLC now owns 2,310 shares of the medical technology company’s stock worth $357,000 after acquiring an additional 363 shares in the last quarter. 75.66% of the stock is currently owned by institutional investors and hedge funds.
SYK has been the topic of a number of recent analyst reports. Royal Bank of Canada reissued a “buy” rating and issued a $175.00 price target on shares of Stryker in a report on Tuesday, January 9th. SunTrust Banks reissued a “buy” rating and issued a $179.00 price target (up previously from $161.00) on shares of Stryker in a report on Friday, January 26th. Guggenheim reissued a “buy” rating on shares of Stryker in a report on Wednesday, January 31st. Piper Jaffray reissued a “buy” rating and issued a $170.00 price target on shares of Stryker in a report on Wednesday, January 31st. Finally, ValuEngine raised shares of Stryker from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and sixteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $165.27.
ILLEGAL ACTIVITY WARNING: “Glenn S. Boehnlein Sells 750 Shares of Stryker Co. (SYK) Stock” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/17/glenn-s-boehnlein-sells-750-shares-of-stryker-co-syk-stock.html.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.